NanoViricides, Inc. (NYSE American: NNVC) announced it has received National Ethics Committee approval in the Democratic Republic of the Congo (DRC) for a Phase II clinical trial evaluating its NV-387 oral gummies as a treatment for the current Bundibugyo ebolavirus outbreak. The company is preparing to submit a Clinical Trial Application to the DRC regulatory agency, ACOREP, and noted that NV-387 drug product is already in the country for an upcoming Phase II Mpox trial, enabling rapid trial initiation if regulatory approval is received.
NanoViricides said NV-387 is the only orally administered Ebola treatment currently under consideration for clinical evaluation, offering potential advantages over infusion-based therapies in resource-limited outbreak settings. The company believes its broad-spectrum antiviral platform, designed to target host-cell features used by viruses, could provide a treatment option for Bundibugyo and other ebolaviruses that currently have no approved therapies or vaccines. To view the full press release, visit https://ibn.fm/MuxOe.
NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug being developed for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections and Measles. The company's advanced drug candidate NV-HHV-1 targets Shingles. NanoViricides is currently focused on advancing NV-387 into Phase II human clinical trials. The company's NV-CoV-2 (API NV-387) is a nanoviricide drug candidate for COVID-19, and NV-CoV-2-R encapsulates remdesivir within its polymeric micelles.
The company's platform technology and programs are based on the TheraCour® nanomedicine technology, which NanoViricides holds a worldwide exclusive perpetual license for several drugs targeting specific human viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex Virus, Varicella-Zoster Virus, Influenza, Dengue, Japanese Encephalitis, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The company intends to obtain licenses for RSV, Poxviruses, and/or Enteroviruses if initial research is successful.
As with any drug development, there can be no assurance that NanoViricides' pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development. The company must state that the path to typical drug development is lengthy and requires substantial capital. For more information, visit the company's newsroom at https://ibn.fm/NNVC.
